{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:18:25Z","timestamp":1792189105223,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Greifswald"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The diagnosis of rare uterine leiomyosarcoma (uLMS) remains a challenge given the high incidence rates of benign uterine tumors such as leiomyoma (LM). In the last decade, several clinical scores and blood serum markers have been proposed. The aim of this study is to validate and update the pLMS clinical scoring system, evaluating the accuracy of the scoring system by Zhang et\u00a0al. and examining the discriminatory ability of blood markers such as serum lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a case-control study, 90 new uLMS from the DKSM consultation registry and 659 prospectively recruited LM cases from the Saarland University Hospital were used for validation. Welch\u2019s t-test and Hedges\u2019\n                      <jats:italic>g<\/jats:italic>\n                      were used to evaluate blood markers and optimal thresholds and diagnostic odds ratios were calculated. Scoring systems were compared using receiver operating characteristics and proposed diagnostic cut-offs were reviewed. Missing values were imputed by random forest imputation to create the updated scoring system \u2018pLMS2\u2019 using penalized logistic regression based on the pooled data sets of 384 uLMS and 1485 LM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>pLMS achieved an AUC of 0.97 on the validation data, but sensitivity and specificity varied at the proposed thresholds due to a shift in the score distributions. 43 uLMS and 578 LM were included in the comparison of pLMS with Zhang\u2019s scoring system, with pLMS being superior (AUC 0.960 vs 0.845). LDH, NLR, and PLR achieved a diagnostic odds ratios of 18.03, 8.64 and 4.81, respectively. pLMS2 is based on subscores for menopausal status interacting with age, tumor diameter, intermenstrual bleeding, hypermenorrhea, dysmenorrhea, postmenstrual bleeding, rapid tumor growth, and suspicious sonography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Validation of the pLMS shows stable discriminatory ability as expressed by AUC, although caution should be taken with cut-off values, as sensitivity and specificity may vary. Data collection of the updated clinical score pLMS2 remains simple and convenient, with no additional cost. The proposed thresholds of 1.5 and 5.5 can be used as a guide to avoid unnecessary or inappropriate surgery and to make the use of further diagnostic measures cost-effective. LDH, NLR and PLR provide further evidence to differentiate uLMS from LM in conjunction with clinical data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-13396-y","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T22:31:26Z","timestamp":1736289086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Validation of biomarkers and clinical scores for the detection of uterine leiomyosarcoma: a case-control study with an update of pLMS"],"prefix":"10.1186","volume":"25","author":[{"given":"Marcus","family":"Vollmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Caroline","family":"Radosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Zygmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"K\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Bralo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Philipp","family":"Radosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Askin Cang\u00fcl","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Krichbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich-Franz","family":"Solomayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kaderali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaher","family":"Alwafai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"1","key":"13396_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"D Day Baird","year":"2003","unstructured":"Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100\u20137. https:\/\/doi.org\/10.1067\/mob.2003.99.","journal-title":"Am J Obstet Gynecol."},{"key":"13396_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/IJWH.S51083","volume":"6","author":"AT Khan","year":"2014","unstructured":"Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health. 2014;6:95.","journal-title":"Int J Womens Health."},{"key":"13396_CR3","doi-asserted-by":"crossref","unstructured":"Halaska MJ, Haidopoulos D, Guyon F, Morice P, Zapardiel I, Kesic V. European Society of Gynecological Oncology statement on fibroid and uterine morcellation. Int J Gynecol Cancer. 2017;27(1):189\u201392.","DOI":"10.1097\/IGC.0000000000000911"},{"issue":"9","key":"13396_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/aogs.12930","volume":"95","author":"M Skorstad","year":"2016","unstructured":"Skorstad M, Kent A, Lieng M. Uterine leiomyosarcoma-incidence, treatment, and the impact of morcellation. A nationwide cohort study. Acta Obstet Gynecol Scand. 2016;95(9):984\u201390.","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"4","key":"13396_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3802\/jgo.2014.25.4.306","volume":"25","author":"SH Tirumani","year":"2014","unstructured":"Tirumani SH, Deaver P, Shinagare AB, Tirumani H, Hornick JL, George S, et al. Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients. JGO. 2014;25(4):306\u201312. https:\/\/doi.org\/10.3802\/jgo.2014.25.4.306.","journal-title":"JGO."},{"issue":"1","key":"13396_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2016.11.002","volume":"144","author":"F Raspagliesi","year":"2017","unstructured":"Raspagliesi F, Maltese G, Bogani G, Fuc\u00e0 G, Lepori S, De Iaco P, et al. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. Gynecol Oncol. 2017;144(1):90\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.002.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"13396_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ygyno.2014.11.011","volume":"137","author":"G Bogani","year":"2015","unstructured":"Bogani G, Cliby WA, Aletti GD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: A systematic review and meta-analysis. Gynecol Oncol. 2015;137(1):167\u201372.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"13396_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/jcm12020591","volume":"12","author":"VM Reichert","year":"2023","unstructured":"Reichert VM, Alwafai Z, Zygmunt MT, Vollmer M, K\u00f6hler G. Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival. J Clin Med. 2023;12(2):591. https:\/\/doi.org\/10.3390\/jcm12020591.","journal-title":"J Clin Med."},{"issue":"1","key":"13396_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2020.10.020","volume":"160","author":"SP Nobre","year":"2021","unstructured":"Nobre SP, Hensley ML, So M, Zhou QC, Iasonos A, Leitao MM Jr, et al. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecol Oncol. 2021;160(1):99\u2013105.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"13396_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.2017.75.9845","volume":"36","author":"S George","year":"2018","unstructured":"George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. J Clin Oncol. 2018;36(2):144. https:\/\/doi.org\/10.1200\/JCO.2017.75.9845.","journal-title":"J Clin Oncol."},{"key":"13396_CR11","doi-asserted-by":"publisher","unstructured":"Akazawa M, Hashimoto K. Artificial intelligence in gynecologic cancers: Current status and future challenges \u2013 A systematic review. Artif Intell Med. 2021;102164. https:\/\/doi.org\/10.1016\/j.artmed.2021.102164.","DOI":"10.1016\/j.artmed.2021.102164"},{"key":"13396_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejrad.2018.11.009","volume":"110","author":"M Malek","year":"2019","unstructured":"Malek M, Gity M, Alidoosti A, Oghabian Z, Rahimifar P, Ebrahimi SMS, et al. A machine learning approach for distinguishing uterine sarcoma from leiomyomas based on perfusion weighted MRI parameters. Eur J Radiol. 2019;110:203\u201311. https:\/\/doi.org\/10.1016\/j.ejrad.2018.11.009.","journal-title":"Eur J Radiol."},{"issue":"2","key":"13396_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.crad.2018.10.010","volume":"74","author":"M Nakagawa","year":"2019","unstructured":"Nakagawa M, Nakaura T, Namimoto T, Iyama Y, Kidoh M, Hirata K, et al. A multiparametric MRI-based machine learning to distinguish between uterine sarcoma and benign leiomyoma: comparison with 18F-FDG PET\/CT. Clin Radiol. 2019;74(2):167-e1. https:\/\/doi.org\/10.1016\/j.crad.2018.10.010.","journal-title":"Clin Radiol."},{"issue":"6","key":"13396_CR14","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00404-019-05344-0","volume":"300","author":"G K\u00f6hler","year":"2019","unstructured":"K\u00f6hler G, Vollmer M, Nath N, Hessler PA, Dennis K, Lehr A, et al. Benign uterine mass - discrimination from leiomyosarcoma by a preoperative risk score: a multicenter cohort study. Arch Gynecol Obstet. 2019;300(6):1719\u201327.","journal-title":"Arch Gynecol Obstet."},{"issue":"5","key":"13396_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/ijgc-2021-003334","volume":"32","author":"M Condic","year":"2022","unstructured":"Condic M, Egger EK, Hohenberger P, Staerk C, Mayr A, Armbrust R, et al. Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA registry. Int J Gynecol Cancer. 2022;32(5):619\u201325. https:\/\/doi.org\/10.1136\/ijgc-2021-003334.","journal-title":"Int J Gynecol Cancer."},{"issue":"7","key":"13396_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/ijgc-2022-003607","volume":"32","author":"M Vollmer","year":"2022","unstructured":"Vollmer M, K\u00f6hler G. Correspondence on \u2018Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry\u2019 by Condic et al. Int J Gynecol Cancer. 2022;32(7):963. https:\/\/doi.org\/10.1136\/ijgc-2022-003607.","journal-title":"Int J Gynecol Cancer."},{"key":"13396_CR17","doi-asserted-by":"publisher","unstructured":"Condic M, Staerk C, Mustea A. Response to: Correspondence on \u2018Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry\u2019 by Vollmer et al. Int J Gynecol Cancer. 2022. https:\/\/doi.org\/10.1136\/ijgc-2022-003662.","DOI":"10.1136\/ijgc-2022-003662"},{"key":"13396_CR18","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.2147\/CMAR.S302223","volume":"13","author":"F Zhang","year":"2021","unstructured":"Zhang F, Liu Y, Quan Q, Meng Y, Mu X. Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System. Cancer Manag Res. 2021;13:4657\u201364. https:\/\/doi.org\/10.2147\/CMAR.S302223.","journal-title":"Cancer Manag Res."},{"key":"13396_CR19","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.2147\/CMAR.S314219","volume":"13","author":"DS Suh","year":"2021","unstructured":"Suh DS, Song YJ, Roh HJ, Lee SH, Jeong DH, Lee TH, et al. Preoperative Blood Inflammatory Markers for the Differentiation of Uterine Leiomyosarcoma from Leiomyoma. Cancer Manag Res. 2021;13:5001\u201311. https:\/\/doi.org\/10.2147\/CMAR.S314219.","journal-title":"Cancer Manag Res."},{"issue":"10","key":"13396_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/diagnostics10100735","volume":"10","author":"H Lawlor","year":"2020","unstructured":"Lawlor H, Ward A, Maclean A, Lane S, Adishesh M, Taylor S, et al. Developing a preoperative algorithm for the diagnosis of uterine leiomyosarcoma. Diagnostics. 2020;10(10):735. https:\/\/doi.org\/10.3390\/diagnostics10100735.","journal-title":"Diagnostics."},{"key":"13396_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s12885-020-07003-z","volume":"20","author":"G Zhang","year":"2020","unstructured":"Zhang G, Yu X, Zhu L, Fan Q, Shi H, Lang J. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer. 2020;20:514. https:\/\/doi.org\/10.1186\/s12885-020-07003-z.","journal-title":"BMC Cancer."},{"issue":"4","key":"13396_CR22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jmig.2019.07.017","volume":"27","author":"SE Lentz","year":"2020","unstructured":"Lentz SE, Zaritsky E, Tucker LY, Lee C, Lazo IM, Niihara A, et al. Prediction of occult uterine sarcoma before hysterectomy for women with leiomyoma or abnormal bleeding. J Minim Invasive Gynecol. 2020;27(4):930\u20137. https:\/\/doi.org\/10.1016\/j.jmig.2019.07.017.","journal-title":"J Minim Invasive Gynecol."},{"key":"13396_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10397-020-01074-3","volume":"17","author":"R Wojdat","year":"2020","unstructured":"Wojdat R, Malanowska E. An evaluation of a Myomscore in the preoperative assessment of uterus myomatosus: a new diagnostic standard? The experience at the Mathilden Hospital in Herford. Germany Gynecol Surg. 2020;17:9. https:\/\/doi.org\/10.1186\/s10397-020-01074-3.","journal-title":"Germany. Gynecol Surg."},{"issue":"1","key":"13396_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1318-7","volume":"4","author":"T Nagai","year":"2015","unstructured":"Nagai T, Takai Y, Akahori T, Ishida H, Hanaoka T, Uotani T, et al. Highly improved accuracy of the revised PREoperative sarcoma score (rPRESS) in the decision of performing surgery for patients presenting with a uterine mass. SpringerPlus. 2015;4(1):1\u20135.","journal-title":"SpringerPlus."},{"key":"13396_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11912-020-00927-6","volume":"22","author":"MJ Halaska","year":"2020","unstructured":"Halaska MJ, Gracia M, Laky R, Zapardiel I. Morcellation of the Uterus: Is There Any Place? Curr Oncol Rep. 2020;22:68. https:\/\/doi.org\/10.1007\/s11912-020-00927-6.","journal-title":"Curr Oncol Rep."},{"key":"13396_CR26","doi-asserted-by":"publisher","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350. https:\/\/doi.org\/10.1136\/bmj.g7594.","DOI":"10.1136\/bmj.g7594"},{"issue":"4","key":"13396_CR27","doi-asserted-by":"publisher","first-page":"e025611","DOI":"10.1136\/bmjopen-2018-025611","volume":"9","author":"P Heus","year":"2019","unstructured":"Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, et al. Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies. BMJ Open. 2019;9(4):e025611.","journal-title":"BMJ Open."},{"key":"13396_CR28","doi-asserted-by":"publisher","unstructured":"Thiele C, Hirschfeld G. cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R. J Stat Softw. 2021;98(11):1\u201327. https:\/\/doi.org\/10.18637\/jss.v098.i11.","DOI":"10.18637\/jss.v098.i11"},{"key":"13396_CR29","doi-asserted-by":"publisher","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;837\u201345. https:\/\/doi.org\/10.2307\/2531595.","DOI":"10.2307\/2531595"},{"issue":"3","key":"13396_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03.","journal-title":"J Stat Softw."},{"key":"13396_CR31","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna; 2022.\u00a0R v4.2.0.\u00a0https:\/\/www.R-project.org\/. Accessed 22 Apr 2022."},{"key":"13396_CR32","doi-asserted-by":"publisher","unstructured":"Kuhn M. Building Predictive Models in R Using the caret Package. J Stat Softw. 2008;28(5):1-26. https:\/\/doi.org\/10.18637\/jss.v028.i05.","DOI":"10.18637\/jss.v028.i05"},{"key":"13396_CR33","unstructured":"Park MY, Hastie T. stepPlr: L2 Penalized Logistic Regression with Stepwise Variable Selection. 2018. R package version 0.93. https:\/\/CRAN.R-project.org\/package=stepPlr. Accessed 28 Jan 2018."},{"key":"13396_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinformatics."},{"issue":"2","key":"13396_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000537730","volume":"89","author":"AS Lagan\u00e0","year":"2024","unstructured":"Lagan\u00e0 AS, Romano A, Vanhie A, Bafort C, G\u00f6tte M, Aaltonen LA, et al. Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper. Gynecol Obstet Investig. 2024;89(2):73\u201386. https:\/\/doi.org\/10.1159\/000537730.","journal-title":"Gynecol Obstet Investig."},{"issue":"199","key":"13396_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-020-01080-1","volume":"20","author":"S Hong","year":"2020","unstructured":"Hong S, Lynn HS. Accuracy of random-forest-based imputation of missing data in the presence of non-normality, non-linearity, and interaction. BMC Med Res Methodol. 2020;20(199):1\u201312. https:\/\/doi.org\/10.1186\/s12874-020-01080-1.","journal-title":"BMC Med Res Methodol."},{"key":"13396_CR37","unstructured":"Akin O. Leiomyosarcoma, Uterus. In: Hricak H, Akin O, Sala E, Ascher SM, Levine D, Reinhold C, editors. Diagnostic imaging gynecology.\u00a0Salt Lake City:\u00a0Amyrsis;\u00a02007. pp. 2:176\u20139."},{"issue":"6","key":"13396_CR38","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2214\/ajr.177.6.1771307","volume":"177","author":"A Sahdev","year":"2001","unstructured":"Sahdev A, Sohaib S, Jacobs I, Shepherd J, Oram D, Reznek R. MR imaging of uterine sarcomas. Am J Roentgenol. 2001;177(6):1307\u201311.","journal-title":"Am J Roentgenol."},{"key":"13396_CR39","doi-asserted-by":"publisher","unstructured":"Virarkar M, Diab R, Palmquist S, Bassett\u00a0Jr R, Bhosale P. Diagnostic Performance of MRI to Differentiate Uterine Leiomyosarcoma from Benign Leiomyoma: A Meta-Analysis. J Belg Soc Radiol. 2020;104(1). https:\/\/doi.org\/10.5334\/jbsr.2275.","DOI":"10.5334\/jbsr.2275"},{"issue":"7","key":"13396_CR40","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1002\/jmri.26630","volume":"49","author":"A Tong","year":"2019","unstructured":"Tong A, Kang SK, Huang C, Huang K, Slevin A, Hindman N. MRI screening for uterine leiomyosarcoma. J Magn Reson Imaging. 2019;49(7):e282\u201394.","journal-title":"J Magn Reson Imaging."},{"key":"13396_CR41","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1007\/s00330-016-4623-9","volume":"27","author":"Y Lakhman","year":"2017","unstructured":"Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, et al. Differentiation of uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and feasibility of texture analysis. Eur Radiol. 2017;27:2903\u201315.","journal-title":"Eur Radiol."},{"issue":"5","key":"13396_CR42","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s00261-024-04198-8","volume":"49","author":"LA Roller","year":"2024","unstructured":"Roller LA, Wan Q, Liu X, Qin L, Chapel D, Burk KS, et al. MRI, clinical, and radiomic models for differentiation of uterine leiomyosarcoma and leiomyoma. Abdom Radiol. 2024;49(5):1522\u201333.","journal-title":"Abdom Radiol."},{"issue":"4","key":"13396_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.tjog.2017.05.003","volume":"56","author":"S Kusunoki","year":"2017","unstructured":"Kusunoki S, Terao Y, Ujihira T, Fujino K, Kaneda H, Kimura M, et al. Efficacy of PET\/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. Taiwan J Obstet Gynecol. 2017;56(4):508\u201313.","journal-title":"Taiwan J Obstet Gynecol."},{"issue":"1","key":"13396_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1447-0756.2012.01915.x","volume":"39","author":"T Kashiyama","year":"2013","unstructured":"Kashiyama T, Oda K, Kawana K, Arimoto T, Kanetaka Y, Takazawa Y, et al. Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer. J Obstet Gynaecol Res. 2013;39(1):424\u20139.","journal-title":"J Obstet Gynaecol Res."},{"issue":"6","key":"13396_CR45","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/cncr.10382","volume":"94","author":"N Kawamura","year":"2002","unstructured":"Kawamura N, Ichimura T, Ito F, Shibata S, Takahashi K, Tsujimura A, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer. 2002;94(6):1713\u201320.","journal-title":"Cancer."},{"key":"13396_CR46","doi-asserted-by":"publisher","unstructured":"Alwafai Z, Reichert V, Spring P, Zygmunt M, K\u00f6hler G. Results of endometrial biopsy and its impact on survival data in patients with high-risk uterine sarcoma.\u00a0J Clin Med. 2024;13(14):4048. https:\/\/doi.org\/10.3390\/jcm13144048.","DOI":"10.3390\/jcm13144048"},{"issue":"4","key":"13396_CR47","doi-asserted-by":"publisher","first-page":"100084","DOI":"10.1016\/j.modpat.2022.100084","volume":"36","author":"A Momeni-Boroujeni","year":"2023","unstructured":"Momeni-Boroujeni A, Yousefi E, Balakrishnan R, Riviere S, Kertowidjojo E, Hensley ML, et al. Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis. Mod Pathol. 2023;36(4):100084. https:\/\/doi.org\/10.1016\/j.modpat.2022.100084.","journal-title":"Mod Pathol."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13396-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:39:46Z","timestamp":1736293186000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13396-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13396"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13396-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the ethics committee of University Medicine Greifswald (Identifier: BB 034\/19a, 2nd March 2021). Written informed consent has been obtained from all patients included in this study for data collection and the use of personal records for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Erich-Franz Solomayer declares financial and non-financial competing interests in cooperation with pharmaceutic companies (Amgen, Astra Zeneca, Celgene, Clovis Oncology, Eisai, Erbe, Gedeon Richter, Genomic Health, GSK, Jenapharm, Johnson Johnson, Medac, Mentor, Novartis, Pfizer, Pierre Fabre, Pharma Mar, MSD, Roche, Roche-Posay, Samsung, Storz, Teva, Vifor) and in memberships or leading position in interest groups (German-Romanian Society of the DGGG, German-Hungarian Society of the DGGG, Association of Saarland Surgeons, DGGG, DEGUM (German Society for Ultrasound in Medicine), AGUB (Working Group for Urogynecology of the DGGG), DGS (German Society for Senology), AGO (Working Group for Gynecological Oncology), German Continence Society, DOG (German Society for Osteooncology), German University Association, ARC Gynecology, Saarland Cancer Society, AGE, German Cancer Society, Endometriosis Research Foundation, European Endometriosis League, Association of Friends of the UKS, Working Group for AGCPC, BLFG, Breast Organ Commission of the AGO, AWMF, Saarland Tumor Center at the UKS e.V., UKS\/ UdS, ETC, ESGE, FOG, MedConcept, BVF). All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}